Feasibility of the InnoVein Valve and Delivery System for Chronic Venous Insufficiency

Overview

This objective of this feasibility study is to evaluate the safety of the InnoVein Valve and Delivery System for treatment of chronic venous insufficiency.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: February 15, 2022

Detailed Description

Chronic Venous Insufficiency occurs when the venous wall and/or valves in the leg veins are not working effectively, making it difficult for blood to return to the heart from the legs.The core etiology of the disease stems from increased venous pressure and incompetent venous valves leading to regurgitation of blood that accumulates in the legs. It has been shown that implantation or recreation of a functional valve can lead to clearance of excess blood and resolution of symptoms. The InnoVein Valve and Delivery System is a new, investigational biocompatible valve intended to support natural flow in vessels in patients with Chronic Venous Insufficiency. The purpose of this study is to assess the safety of the InnoVein Valve and Delivery System for treatment of Chronic Venous Insufficiency.

Interventions

  • Device: InnoVein Valve Treatment
    • Subjects will have the InnoVein Valve implanted

Arms, Groups and Cohorts

  • Experimental: Treatment
    • Subjects will have the InnoVein Valve implanted

Clinical Trial Outcome Measures

Primary Measures

  • Safety of the InnoVein Valve and Delivery System: Number of Major Adverse Events
    • Time Frame: 30 Days
    • Number of Major Adverse Events

Participating in This Clinical Trial

Key Inclusion Criteria:

  • Willing and able to provide written Informed Consent – Diagnosis of symptomatic non-obstructive chronic valvular insufficiency of the femoral vein – Willing and medically able to receive intraprocedural and post-procedural anticoagulation medication – Life expectancy >1yr – Reflux time >1s in the superficial femoral and/or popliteal vein Key Exclusion Criteria:

  • Any prior deep vein intervention within 6 months prior to the Index Procedure – History of 2+ DVTs – Inadequate inflow to the femoral vein or inadequate outflow through the femoral vein, iliac vein, or IVC – Current IVC Placement – History of pulmonary embolism within 6 months – Conditions that increase the risk of device thrombosis or patient bleeding – Any planned surgical or interventional procedure within 30 days prior to or after the Index Procedure – Investigator or sponsor believes the subject would not benefit, would not be appropriate, be unable to follow-up, or be at high risk for non-compliance with the protocol

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • InnoVein
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • InnoVen Data Management, 650-302-0847, IM-CP-2001@innoveinmedical.com

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.